As of June 7, 2025, Strongbridge Biopharma plc (SBBP) reports a Net Margin of -146.70%.
Net Margin shows the share of revenue that becomes profit after all costs, reflecting overall profitability.
Historical Trend of Strongbridge Biopharma plc's Net Margin
Over recent years, Strongbridge Biopharma plc's Net Margin has shown a stable trend. The table below summarizes the historical values:
| Date | Net Margin |
|---|---|
| 2020-12-31 | -146.70% |
| 2019-12-31 | -227.78% |
| 2018-12-31 | 176.65% |
| 2017-12-31 | -1609.65% |
This slight upward trend highlights how Strongbridge Biopharma plc manages its overall profitability and cost control over time.
Comparing Strongbridge Biopharma plc's Net Margin to Peers
To better understand Strongbridge Biopharma plc's position, it's useful to compare its Net Margin against industry peers. Below are selected comparisons:
| Company | Net Margin |
|---|---|
| Strongbridge Biopharma plc (SBBP) | -146.70% |
| AcelRx Pharmaceuticals Inc (ACRX) | 2698.31% |
| SOL Global Investments Corp (SOL.CN) | 133.62% |
| Royalty Pharma PLC (RPRX) | 37.95% |
| Next Green Wave Holdings Inc (NGW.CN) | 27.40% |
| Zoetis Inc (ZTS) | 26.86% |
Compared to its competitors, Strongbridge Biopharma plc's Net Margin is about average compared to peers, reflecting typical industry profitability.